← Back to Search

MRI Scanning for Pancreatic Cancer Detection (DWI-PDAC Trial)

N/A
Recruiting
Led By Alexandre Brind'Amour, MD
Research Sponsored by Laval University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
CA 19-9 ≥ 400 U/mL with normal bilirubin level (< 40)
Tumor size ≥ 3 cm
Must not have
Patient unfit for pancreatic resection (ECOG 2 or more)
Tumor size < 3 cm
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 months
Awards & highlights

Summary

This trial is looking at whether adding a MRI scan to the usual CT scan helps doctors better understand if a person with pancreatic cancer also has cancer in the lining of their abdomen.

Who is the study for?
This trial is for individuals with confirmed pancreatic ductal adenocarcinoma that can potentially be removed by surgery. They should have a tumor size of at least 3 cm and elevated CA 19-9 levels without distant metastases. Participants must be physically fit enough for pancreatic resection (ECOG performance status of 0 or 1).Check my eligibility
What is being tested?
The study is testing the effectiveness of whole-body diffusion-weighted MRI in detecting peritoneal metastases in patients with high-risk pancreatic cancer, comparing its results to those from CT scans and correlating them with findings during surgery.See study design
What are the potential side effects?
As this trial involves diagnostic imaging, there are minimal side effects associated with MRI; however, some may experience discomfort or anxiety in the scanner. There's also a small risk of an allergic reaction to any contrast material if used.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My CA 19-9 levels are high, but my bilirubin is normal.
Select...
My tumor is larger than 3 cm.
Select...
My cancer has not spread to distant parts of my body.
Select...
I am fit for surgery to remove part of my pancreas.
Select...
My disease can potentially be removed with surgery, as shown by a CT scan.
Select...
I have been diagnosed with pancreatic cancer.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am not fit for pancreatic surgery due to my physical condition.
Select...
My tumor is smaller than 3 cm.
Select...
My CA 19-9 levels are below 400 U/mL or above without prior drainage.
Select...
My CT scan shows my disease is advanced but not spread far.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Peritoneal findings
Unexpected abortion
Secondary outcome measures
Early distant recurrence

Trial Design

1Treatment groups
Experimental Treatment
Group I: DWI-MRIExperimental Treatment1 Intervention
Patients to undergo DWI-MRI (patients include in the study.

Find a Location

Who is running the clinical trial?

Laval UniversityLead Sponsor
422 Previous Clinical Trials
172,806 Total Patients Enrolled
Alexandre Brind'Amour, MDPrincipal InvestigatorLaval University
2 Previous Clinical Trials
41 Total Patients Enrolled

Media Library

Whole-body diffusion-weighted magnetic resonance imaging Clinical Trial Eligibility Overview. Trial Name: NCT05340569 — N/A
Pancreatic Adenocarcinoma Research Study Groups: DWI-MRI
Pancreatic Adenocarcinoma Clinical Trial 2023: Whole-body diffusion-weighted magnetic resonance imaging Highlights & Side Effects. Trial Name: NCT05340569 — N/A
Whole-body diffusion-weighted magnetic resonance imaging 2023 Treatment Timeline for Medical Study. Trial Name: NCT05340569 — N/A
~12 spots leftby Jul 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top